Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MORPHEUS-HR+ Breast Cancer umbrella trial
MOH_2018-11-01_003728Phase 2Not yet recruiting
- Sponsor
- Roche
- Start
- Sep 2018
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab, ipatasertib, fulvestrant, entinostat, bevacizumab and 2 more in breast cancer (6 arms), sponsored by Roche. Primary endpoint: Efficacy. Planned start Sep 2018; status: not yet recruiting.
02
Drugs
atezolizumabipatasertibfulvestrantentinostatbevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2018-11-01_003728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-11-01_003728.